
A federal health panel has voted for the first time to make the HPV test — rather than the Pap smear — the preferred way to screen women aged 30 to 65 for cervical cancer, a change that could affect how millions of American women are tested. Members of the US Preventive Services Task Force reached the decision behind closed doors on Friday, November 20, 2026, at the end of a two-day meeting. The recommendation is not yet final, and it is unclear when it will be published.
The vote came at the end of the panel's two-day meeting, its first in more than a year and its first since Health Secretary Robert F. Kennedy Jr. reshaped it in September by naming eight new members.
For women aged 30 to 65, primary testing for high-risk HPV — the virus behind virtually all cervical cancers — would become the recommended approach, replacing a choice between a Pap test, an HPV test or both. The panel also backed self-collection, letting women take their own sample with a simple vaginal swab rather than undergoing a speculum exam.
It is not yet clear whether Kennedy will need to sign off on the recommendation or seek changes. A Supreme Court ruling last year affirmed his authority over the panel.
Cervical cancer is one of the most preventable cancers, and screening is the reason why. The disease usually develops slowly, over many years, from persistent infection with high-risk types of HPV. A test that catches the virus early gives doctors time to treat the problem long before it becomes cancer.
For decades the Pap smear was the standard tool. A clinician collects cells from the cervix during a speculum exam, and a laboratory checks them for abnormal changes. The test works, but it has limits: it catches roughly 50 to 70 percent of abnormalities, and it needs an in-person exam that some women find uncomfortable or hard to arrange.
HPV testing works differently. Instead of looking for abnormal cells, it looks for the virus itself. A large 2018 study in JAMA, following more than 19,000 women, found HPV tests detected precancerous changes earlier and more accurately than Pap tests. The American Cancer Society has prioritised HPV testing since 2020, starting screening at 25.
Under the task force's current guidance, women aged 30 to 65 can choose a Pap test every three years, an HPV test every five years, or both together every five years. The new vote would make primary HPV testing the preferred route. Screening would still stop at 65, but only for women with several negative results in a row over the previous decade.
For women aged 30 to 65, the practical change is simple: the HPV test, normally done every five years, would become the default, rather than one of three equal choices. The bigger change may be self-collection. A swab a woman can use herself, without a speculum exam, is expected to widen access — including through mobile clinics and laboratories — and to reach women who skip screening because the exam itself puts them off, including women in rural areas and women without a regular clinician.
The American Cancer Society has long been ahead of the task force on this question, prioritising HPV testing since 2020 and starting screening at 25. Its position gives the new vote a strong endorsement from the country's largest cancer organisation.
The American College of Obstetricians and Gynecologists said it is monitoring the task force's process and will evaluate the final proposed changes when they are available. The cautious reply reflects the fact that the recommendation is not yet final: until the text is published, medical groups cannot say exactly what they will advise.
The main uncertainty is Health Secretary Robert F. Kennedy Jr. Whether he will approve the recommendation as voted, seek changes or delay publication is not yet known.
The stakes are practical. Task force recommendations carry real weight because, under the Affordable Care Act, most private insurers must cover recommended services at no cost to patients. A preferred HPV test would therefore be free for most insured women, removing a cost barrier to screening.
It also matters because earlier detection saves lives. HPV tests find precancerous changes sooner and more reliably than Pap tests, and self-collection could bring in women who have avoided screening altogether. Cervical cancer is highly preventable when caught early — the gap is not medicine, but getting women tested.
The next step is publication of the final recommendation, which will set the exact wording, the screening interval and how self-collection should be offered. Until then, women should keep to their current screening schedule and talk to their clinician about what the change will mean for them.
Attention will also stay on the health department, where the question of Kennedy's sign-off remains open. Once the final guidance appears, insurers and clinicians will update their own advice — and the new HPV-first approach will start reaching exam rooms across the country.
What is an HPV test?
A laboratory test that looks for high-risk types of human papillomavirus, the virus behind virtually all cervical cancers, rather than checking cells for abnormal changes.
Does the new guidance replace the Pap smear?
For women aged 30 to 65, the HPV test would become the preferred test. Women aged 21 to 29 would still be advised to have a Pap test every three years.
What is a self-collected HPV test?
A test in which a woman collects her own sample with a simple vaginal swab, without a speculum exam, and sends it to a laboratory.
When does the new guidance take effect?
Not yet. The task force has voted, but the recommendation is not final and no publication date has been announced.
Will insurance cover the HPV test?
Under the Affordable Care Act, most private insurers must cover task force-recommended screening at no cost to patients.
Read more: American Cancer Society Urges Routine Prostate Cancer Screening for Men 50 to 69 | US Measles Cases Surge Past 7,700 as 13 Deaths Reported in 2026 | Estrogen Patch Black Box Warning Removed for Three Menopause Products by FDA